Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Bennett, P. Weinberg, K. Rozenberg-Ben-Dror, P. Yarnold, H. Kwaan, D. Green (1998)
Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine: A Review of 60 CasesAnnals of Internal Medicine, 128
K. Mak, G. Belli, S. Ellis, D. Moliterno (1996)
Subacute stent thrombosis: evolving issues and current concepts.Journal of the American College of Cardiology, 27 2
MD Colombo, MD Hall, MD Nakamura, MD Almagor, MD Maiello, Ccp Martini, MD Gaglione, MD Goldberg, MD Tobis (1995)
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.Circulation, 91 6
I. Moussa, C. Mario, B. Reimers, T. Akiyama, J. Tobis, A. Colombo (1997)
Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.Journal of the American College of Cardiology, 29 1
N Engl J Med, 338
D. Antoniucci, R. Valenti, G. Santoro, L. Bolognese, M. Trapani, G. Cerisano, Vieri Boddi, Pier Fazzini (1998)
Restenosis after coronary stenting in current clinical practice.American heart journal, 135 3
Lancet, 349
Epic Investigators (1994)
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.The New England journal of medicine, 330 14
Mark Mark, Talley Talley, Topol Topol (1996)
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high‐risk coronary angioplastyCirculation, 94
Circulation, 96
E. Plow, G. Marguerie, M. Ginsberg (1987)
Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions.Biochemical pharmacology, 36 23
E. Kaplan, P. Meier (1958)
Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 53
P. Ruygrok, P. Serruys (1996)
Intracoronary stenting. From concept to custom.Circulation, 94 5
E. Topol, R. Califf, H. Weisman, S. Ellis, J. Tcheng, S. Worley, R. Ivanhoe, B. George, D. Fintel, M. Weston, K. Sigmon, K. Anderson, Kerry Lee, JamesT. Willerson (1994)
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 343
Integrilin Thrombosis-II (1997)
Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-IIThe Lancet, 349
A. Schömig, Franz‐Josef Neumann, A. Kastrati, H. Schühlen, R. Blasini, M. Hadamitzky, H. Walter, E. Zitzmann-Roth, G. Richardt, E. Alt, C. Schmitt, K. Ulm (1996)
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.The New England journal of medicine, 334 17
Annie Andrieux, G. Hudry‐Clergeon, J. Ryckewaert, Agnès Chapel, M. Ginsberg, E. Plow, G. Marguerie (1989)
Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GPIIbIIIa.The Journal of biological chemistry, 264 16
F. Fernández‐Avilés, J. Alonso, J. Durán, F. Gimeno, J. Muñoz, L. Fuente, J. Román (1996)
Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.Journal of the American College of Cardiology, 27 1
J. Lefkovits, E. Plow, E. Topol (1995)
Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.The New England journal of medicine, 332 23
Epilog Investigators (1997)
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.The New England journal of medicine, 336 24
D. Kereiakes, Neal Kleiman, James Ferguson, A. Masud, T. Broderick, C. Abbottsmith, J. Runyon, Linda Anderson, Robert Anders, Roger Dreiling, Gary Hantsbarger, Brian Bryzinski, E. Topol (1998)
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.Circulation, 98 13
D. Vorchheimer, Valentin Fuster (1998)
Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.Circulation, 97 4
D. Hasdai, K. Garratt, D. Holmes, P. Berger, R. Schwartz, M. Bell (1996)
Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis.Journal of the American College of Cardiology, 28 2
D. Kereiakes (1998)
Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state.The American journal of cardiology, 81 7A
M. Haude, R. Erbel, H. Issa, U. Straub, H. Rupprecht, N. Treese, J. Meyer (1993)
Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents.American heart journal, 126 1
E. Topol, J. Ferguson, H. Weisman, J. Tcheng, Stephen Ellis, N. Kleiman, R. Ivanhoe, Ann Wang, David Miller, K. Anderson, R. Califf (1997)
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.JAMA, 278 6
Kereiakes Kereiakes, Kleiman Kleiman, Ferguson Ferguson (1998)
Pharmacodynamic efficiency, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofibanCirculation, 98
T. Investigators (1998)
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.Lancet, 352 9122
Topol Topol, Ferguson Ferguson, Weisman Weisman (1997)
Long‐term protection from myocardial ischemic events in a randomized trial of brief integrin beta‐3 blockade with percutaneous coronary interventionJAMA, 278
N Engl J Med, 338
J. Tcheng, R. Harrington, K. Kottke-Marchant, N. Kleiman, S. Ellis, D. Kereiakes, M. Mick, F. Navetta, J. Smith, S. Worley, Joyce Miller, Diane Joseph, K. Sigmon, M. Kitt, C. Mee, R. Califf, E. Topol (1995)
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary InterventionCirculation, 91
(2017)
UvA-DARE ( Digital Academic Repository ) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina : the CAPTURE study
N Engl J Med, 338
T. Investigators (1997)
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.Circulation, 96 5
G. Karrillon, M. Morice, E. Benveniste, P. Bunouf, P. Aubry, S. Cattan, B. Chevalier, P. Commeau, A. Cribier, C. Eiferman, G. Grollier, Y. Guérin, M. Henry, T. Lefévre, B. Livarek, Y. Louvard, J. Marco, Serge Makowski, J. Monassier, J. Pernès, P. Rioux, C. Spaulding, G. Zemour (1996)
Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry.Circulation, 94 7
D. Fischman, M. Leon, D. Baim, R. Schatz, M. Savage, I. Penn, K. Detre, L. Veltri, D. Ricci, M. Nobuyoshi (1994)
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.The New England journal of medicine, 331 8
Serruys Serruys, Jaegere Jaegere, Kiemeneij Kiemeneij (1994)
A comparison of balloon‐expandable‐stent implantation with balloon angioplasty in patients with coronary artery diseaseN Engl J Med, 331
Fischman Fischman, Leon Leon, Baim Baim (1994)
A randomized comparison of coronary‐stent placement and balloon angioplasty in the treatment of coronary artery diseaseN Engl J Med, 331
P. Serruys, P. Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heyndrickx, H. Emanuelsson, J. Marco, V. Legrand, P. Materne, J. Belardi, U. Sigwart, A. Colombo, J. Goy, P. Heuvel, J. Delcán, M. Morel (1994)
A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.The New England journal of medicine, 331 8
V. Fuster, P. Adams, J. Badimón, J. Chesebro (1987)
Platelet-inhibitor drugs' role in coronary artery disease.Progress in cardiovascular diseases, 29 5
D. Mark, J. Talley, E. Topol, Lee Bowman, L. Lam, K. Anderson, J. Jollis, M. Cleman, Kerry Lee, Thomas Aversano, William Untereker, L. Davidson-Ray, R. Califf (1996)
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.Circulation, 94 4
Clinical trials have demonstrated the efficacy of glycoprotein (GP) IIb/IIIa antagonists in preventing the thrombotic end points of death, myocardial infarction, and urgent revascularization when they are administered at the time of percutaneous coronary revascularization (PTCR). It has been postulated that prolongation of receptor blockade beyond acute intervention would extend the clinical benefit of these agents. The Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE) study was a multicenter, international, randomized placebo‐controlled trial of the oral GP IIb/IIIa antagonist Xemilofiban administered prior to and after PTCR. The study was designed to assess the efficacy and safety of continuing oral xemilofiban for 6 months to prevent these primary thrombotic end points. More than 7,200 patients were randomized in 29 countries to receive placebo or one of two doses of xemilofiban. Stenting was performed at the discretion of the operator. All patients received aspirin and periprocedural heparin; all stented patients received continuous xemilofiban, or ticlopidine for 2–4 weeks followed by xemilofiban‐placebo. Most patients were also evaluated 1 month after conclusion of the study drug treatment. Clinical data from up to 6 months of drug treatment and 1 month posttreatment were used to evaluate the acute and long‐term efficacy and safety of xemilofiban. Secondary end points included the need for any revascularization, repeat hospitalization for unstable angina, and nonhemorrhagic stroke. The cumulative incidence of bleeding events and effects of xemilofiban in stented and nonstented patients were evaluated. The efficacy of continuing xemilofiban and aspirin therapy as the sole antithrombotic medications following stent deployment was assessed against a ticlopidine and aspirin control group. The incremental clinical benefit of long‐term receptor blockade over acute receptor antagonism was evaluated.
Journal of Interventional Cardiology – Wiley
Published: Apr 1, 1999
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.